IP Library › Granted Patent US 12,435,035
Granted Patent B2
US 12,435,035 · App. 17/142,595 · Granted Oct 7, 2025

Nanomaterials

Inventors: Gregory Lawrence Hamilton (Atlanta, GA); Neeraj Narendra Patwardhan (Atlanta, GA); Cory Dane Sago (Atlanta, GA); Mina Fawzy Gaballa Shehata (Dunwoody, GA); Milloni Balwantkumar Chhabra (Dunwoody, GA)
Assignee: Guide Therapeutics, LLC
C07D205/04A61K9/1271A61K47/10A61K47/24A61K47/28C07C229/30C07D207/06C07D207/09C07D211/14C07D211/34C07D265/30C07D295/145C07D319/06C07D401/04C07D405/12C07D471/04C07D487/08A61K9/5123B82Y5/00B82Y30/00B82Y40/00C07C219/22C07D207/08C07D207/14C07D207/16C07D211/58C07D211/62C07D213/36C07D241/04C07D243/08C07D295/088C07D295/096C07D295/13C07D295/15C07D451/06C07D455/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,035
App. No.
17/142,595
Granted
Oct 7, 2025
Kind
B2
Abstract

Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand are also provided.

Claims (3)

1. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

2. A lipid nanoparticle (LNP) comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (5)
SECURITY INTEREST Recorded Mar 6, 2026
From: BEAM THERAPEUTICS INC.
To: SIXTH STREET LENDING PARTNERS, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0929 →
SECURITY INTEREST Recorded Mar 6, 2026
From: GUIDE THERAPEUTICS, LLC
To: SIXTH STREET LENDING PARTNERS, AS ADMINISTRATIVE AGENT
Reel/Frame 075022/0001 →
SECURITY INTEREST Recorded Feb 24, 2026
From: BEAM THERAPEUTICS INC.; GUIDE THERAPEUTICS, LLC; BBBR, LLC
To: SIXTH STREET LENDING PARTNERS, AS ADMINISTRATIVE AGENT
Reel/Frame 074955/0064 →
MERGER AND CHANGE OF NAME Recorded Jun 20, 2022
From: GUIDE THERAPEUTICS, INC.; GALILEO MERGER SUB II, LLC
To: GUIDE THERAPEUTICS, LLC
Reel/Frame 060253/0251 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2021
From: HAMILTON, GREGORY LAWRENCE; PATWARDHAN, NEERAJ NARENDRA; SAGO, CORY DANE; SHEHATA, MINA FAWZY GABALLA; CHHABRA, MILLONI BALWANTKUMAR
To: GUIDE THERAPEUTICS, INC.
Reel/Frame 055324/0573 →
Continuity (2)
Provisional Application 62958876 · Jan 9, 2020
Related Publication 20210230112A1 · Jul 29, 2021
References Cited (154)
US 3686238A · Zaffaroni · 1972 [cited by applicant]
US 8058069B2 · Yaworski et al. · 2011 [cited by applicant]
US 9364435B2 · Yaworski et al. · 2016 [cited by applicant]
US 9840699B2 · Liu et al. · 2017 [cited by applicant]
US 10113163B2 · Liu et al. · 2018 [cited by applicant]
US 10124065B2 · Baryza et al. · 2018 [cited by applicant]
US 10167457B2 · Liu et al. · 2019 [cited by applicant]
US 20030083272A1 · Wiederholt et al. · 2003 [cited by applicant]
US 20160311759A1 · Brito et al. · 2016 [cited by applicant]
US 20170210698A1 · Benenato et al. · 2017 [cited by applicant]
US 20180147166A1 · Dong et al. · 2018 [cited by applicant]
US 20180290965A1 · Brito et al. · 2018 [cited by applicant]
US 20190002393A1 · Beckwith et al. · 2019 [cited by applicant]
US 20190076462A1 · Dong et al. · 2019 [cited by applicant]
US 20190358170A1 · Brito et al. · 2019 [cited by applicant]
US 20210113365A1 · Kim · 2021 [cited by applicant]
US 20210130805A1 · Gaudelli et al. · 2021 [cited by applicant]
US 20210169804A1 · Patwardhan et al. · 2021 [cited by applicant]
US 20210230112A1 · Hamilton et al. · 2021 [cited by applicant]
US 20220096381A1 · Endo et al. · 2022 [cited by applicant]
US 20220249693A1 · Sago et al. · 2022 [cited by applicant]
US 20220249694A1 · Shehata et al. · 2022 [cited by applicant]
US 20220273566A1 · Dahlman et al. · 2022 [cited by applicant]
US 20230348359A1 · Shehata et al. · 2023 [cited by applicant]
AU 2020369940A1 · 2022 [cited by applicant]
CN 108368028A · 2018 [cited by applicant]
CN 110520409A · 2019 [cited by applicant]
EP 1164125A1 · 2001 [cited by applicant]
EP 3733211A1 · 2020 [cited by applicant]
EP 3842538A1 · 2021 [cited by applicant]
EP 4069675A1 · 2022 [cited by applicant]
GB 968849A · 1964 [cited by applicant]
JP 2005181734A · 2005 [cited by applicant]
WO 0244321A2 · 2002 [cited by applicant]
WO 03101952A2 · 2003 [cited by applicant]
WO 2008155141A2 · 2008 [cited by applicant]
WO 2011153493A2 · 2011 [cited by applicant]
WO 2013086354A1 · 2013 [cited by applicant]
WO 2014136086A1 · 2014 [cited by applicant]
WO 2015095346A1 · 2015 [cited by applicant]
WO WO2015095340A1 · 2015 [cited by applicant]
WO 2016187531A1 · 2016 [cited by applicant]
WO 2017173054A1 · 2017 [cited by applicant]
WO 2018011799A1 · 2018 [cited by applicant]
WO 2018220553A1 · 2018 [cited by applicant]
WO 2019008441A1 · 2019 [cited by applicant]
WO 2019089561A1 · 2019 [cited by applicant]
WO 2019099501A1 · 2019 [cited by applicant]
WO 2019126378A1 · 2019 [cited by applicant]
WO 2020028787A1 · 2020 [cited by applicant]
WO 2020072605A1 · 2020 [cited by applicant]
WO 2020118041A1 · 2020 [cited by applicant]
WO 2020150320A1 · 2020 [cited by applicant]
WO 2020152037A1 · 2020 [cited by applicant]
WO 2020176856A1 · 2020 [cited by applicant]
WO 2020176859A1 · 2020 [cited by applicant]
WO 2020176868A1 · 2020 [cited by applicant]
WO WO2020219876A1 · 2020 [cited by applicant]
WO 2020246581A1 · 2020 [cited by applicant]
WO 2020247382A1 · 2020 [cited by applicant]
WO 2021021634A1 · 2021 [cited by applicant]
WO 2021021636A1 · 2021 [cited by applicant]
WO 2021080847A1 · 2021 [cited by applicant]
WO 2021113365A1 · 2021 [cited by applicant]
WO 2021141969A1 · 2021 [cited by applicant]
WO 2022140238A1 · 2022 [cited by applicant]
WO 2022140239A1 · 2022 [cited by applicant]
WO 2022140252A1 · 2022 [cited by applicant]
WO 2022159421A1 · 2022 [cited by applicant]
WO 2022159463A1 · 2022 [cited by applicant]
WO 2022159472A1 · 2022 [cited by applicant]
WO WO2022159475A1 · 2022 [cited by applicant]
WO 2022251665A1 · 2022 [cited by applicant]
WO 2023056917A1 · 2023 [cited by applicant]
WO 2023121964A1 · 2023 [cited by applicant]
WO 2023121965A1 · 2023 [cited by applicant]
WO 2023121970A1 · 2023 [cited by applicant]
WO 2023121971A1 · 2023 [cited by applicant]
WO 2023121975A1 · 2023 [cited by applicant]
WO 2024019936A1 · 2024 [cited by applicant]
Brown and Foote, Organic Chemistry 1995, Saunders College Publishing: Fort Worth, p. 169. [cited by examiner]
Funakoshi “Effect of Alkyl Chain Length and Unsaturation of the Phospholipid on the Physicochemical Properties of Lipid Nanoparticles” Chem. Pharm. Bull. 2015, 63, 731-736. [cited by examiner]
International Search Report and Written Opinion dated Mar. 3, 2021 for Application No. PCT/US2021/012282. [cited by applicant]
CAS Registry No. 751440-44-5; STN Entry Date Sep. 24, 2004; 3-octyl-6-[7-oxo-7-[[2-[(1-oxooctadecyl)oxy]-1-[[(oxooctadecyl)oxy]methyl]ethoxy]heptyl]-4-Cyclohexene-1,2-dicarboxylic acid, (1 page). [cited by applicant]
International Search Report and Written Opinion for PCT/US2020/062893 dated Feb. 19, 2021 (19 pages). [cited by applicant]
International Search Report for PCT/US22/12951 dated May 23, 2022 (5 pages). [cited by applicant]
International Search Report for PCT/US2022/012867 dated Jun. 8, 2022 (5 pages). [cited by applicant]
International Search Report for PCT/US2022/053209 dated Mar. 24, 2023 (5 pages). [cited by applicant]
International Search Report for PCT/US2022/053193 dated May 3, 2023 (4 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2020/043512 dated Sep. 23, 2020 (16 pages). [cited by applicant]
“SID 402741750”, PubChem, National Center for Biotechnology Information, SID 402741750, Jan. 23, 2020, retrieved Mar. 21, 2022 from URL: https://pubchem.ncbi.nlm.nih.gov/substance/402741750, (5 pages). [cited by applicant]
“SID 46481541”, PubChem, National Center for Biotechnology Information, SID 46481541, Dec. 12, 2007, retrieved May 10, 2022 from URL: https://pubchem.ncbi.nlm.nih.gov/substance/46481541, (5 pages). [cited by applicant]
“Tris(deoxycholic acid) 1,3,5-benzenetriyltris(methylene) ester”, PubChem, National Center for Biotechnology Information, SID 274013917, Dec. 18, 2015, retrieved Mar. 21, 2022 from URL: https://pubchem.ncbi.nlm.nih.gov/… [cited by applicant]
Adams, David, et al., “Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis”, The New England Journal of Medicine, vol. 379, No. 1, Jul. 5, 2018, pp. 11-21, DOI: 10.1056/NEJMoa1716153 (11 pages). [cited by applicant]
Augustin, Hellmut G., et al., “Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology”, Science, vol. 357, No. 771, Aug. 25, 2017, DOI: 10.1126/science.aal2379 (13 pages). [cited by applicant]
Belliveau, Nathan M., et al., “Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vitro Delivery of siRNA”, Molecular Therapy—Nucleic Acids, vol. 1, No. e37, 2012, DOI: 10.1038/mtna.2012.28 (9… [cited by applicant]
Chen, Delai, et al., “Rapid Discovery of Potent siRNA-Containing Lipid Nanoparticles Enabled by Controlled Microfluidic Formulation”, Journal of the American Chemical Society, vol. 134, No. 16, Apr. 25, 2012, pp. 6948-6… [cited by applicant]
Cheng, Zhiliang, et al., “Multifunctional Nanoparticles: Cost versus benefit of adding targeting and imaging capabilities”, Science, vol. 338, No. 6109, Nov. 16, 2012, pp. 903-910, DOI: 10.1126/science.1226338 (18 pages… [cited by applicant]
Cullis, Pieter R., et al., “Lipid Nanoparticle Systems for Enabling Gene Therapies”, Molecular Therapy, vol. 25, No. 7, Jul. 5, 2017, pp. 1467-1475, DOI: 10.1016/j.ymthe.2017.03.013 (9 pages). [cited by applicant]
Dahlman, James E., et al., “In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight”, Nature Nanotechnology, vol. 9, No. 8, Aug. 2014, pp. 648-655, DOI: 10.1038/nnano.2014.84 (17 pages… [cited by applicant]
Dang, Chi V., et al., “Drugging the ‘undruggable’ cancer targets”, Nature Reviews Cancer, vol. 17, No. 8, Aug. 2017, pp. 502-508, DOI: 10.1038/nrc.2017.36, Author Manuscript (16 pages). [cited by applicant]
Diab, Hadeer M., et al., “ZnO-Nanoparticles-Catalyzed Synthesis of Poly(tetrahydrobenzimidazo[2, 1-b]quinazolin-1(2H)-ones) as Novel Multi-armed Molecules”, Synlett, vol. 29, No. 12, 2018, pp. 1627-1633, DOI: 10.1055/s-… [cited by applicant]
Dixon, Scott J., et al., “Identifying Druggable Disease-Modifying Gene Products”, Current Opinion in Chemical Biology, vol. 13, No. 5-6, Dec. 2009, pp. 549-555, DOI: 10.1016/j.cbpa.2009.08.003, Author Manuscript (12 pag… [cited by applicant]
Elbashir, Sayda M., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”, Nature, vol. 411, May 24, 2001, pp. 494-498 (5 pages). [cited by applicant]
Gelsema, W. J., et al., “Benzoolysis of diacylglycerophosphocholines: dephosphorylation and sequential formation of isomeric reaction products”, Journal of Lipid Research, vol. 37, 1996, pp. 1224-1233 (10 pages). [cited by applicant]
Heidenreich, Olaf, et al., “High Activity and Stability of Hammerhead Ribozymes Containing 2′-Modified Pyrimidine Nucleosides and Phosphorothioates”, The Journal of Biological Chemistry, vol. 269, Jan. 21, 1994, pp. 213… [cited by applicant]
Jenkins, Russell W., et al., “Mechanisms of resistance to immune checkpoint inhibitors”, British Journal of Cancer, vol. 118, No. 1, Jan. 2018, pp. 9-16, DOI: 10.1038/bjc.2017.434 (8 pages). [cited by applicant]
Junquera, Elena, et al., “Recent progress in gene therapy to deliver nucleic acids with multivalent cationic vectors”, Advances in Colloid and Interface Science, vol. 233, 2016, pp. 161-175, (15 pages). [cited by applicant]
Karikó, Katalin, et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability”, Molecular Therapy, vol. 16, No. 11, Nov. 2008, pp… [cited by applicant]
Kedmi et al., “A modular platform for targeted RNAi therapeutics”, Nature Nanotechnology, vol. 13, Jan. 29, 2018, pp. 214-219, DOI: 10.1038/s41565-017-0043-5, 214-219 (6 pages). [cited by applicant]
Khalil, Danny N., et al., “The future of cancer treatment: immunomodulation, CARs and combination immunotherapy”, Nature Reviews: Clinical Oncology, vol. 13, No. 5, May 2016, pp. 273-290, DOI: 10.1038/nrclinonc.2016.25,… [cited by applicant]
Kozak, Marilyn, “An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs”, Nucleic Acids Research, vol. 15, No. 20, 1987, pp. 8125-8148 (24 pages). [cited by applicant]
Kumar, Priti, et al., “T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice”, Cell, vol. 134, Aug. 22, 2008, pp. 577-586, DOI: 10.1016/j.cell.2008.06.034 (10 pages). [cited by applicant]
Leung, Alex K., et al., “Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core”, The Journal of Physical Chemistry, vol. 116, No. 34, Jul. 18, 2012, pp. 18… [cited by applicant]
Lokugamage, Melissa P., et al., “Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands”, Advanced Materials, vol. 31, Issue 41, No. 1902251, Aug. 29, 2019, DOI: 10.1002/adma.2019… [cited by applicant]
Lokugamage, Melissa P., et al., “Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands”, Advanced Materials, vol. 31, Issue 41, No. 1902251, Aug. 29, 2019, DOI: 10.1002/adma.2019… [cited by applicant]
Lokugamage, Melissa P., et al., “Testing thousands of nanoparticles in vivo using DNA barcodes”, Current Opinion: Biomedical Engineering, vol. 7, Sep. 2018, p. 1-8, DOI: 10.1016/j.cobme.2018.08.001, Author Manuscript (1… [cited by applicant]
Lorenzer, Cornelia, et al., “Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics”, Journal of Controlled Release, vol. 203, Apr. 10, 2015, pp. 1-15, DOI: 10.1016/j.jconrel.2015.02.… [cited by applicant]
Macparland, Sonya A., et al., “Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood”, ACS Nano, vol. 11, 2017, pp. 2428-2443, DOI: 10.1021/acsnano.6b06245 (16 pages). [cited by applicant]
Makarova, Kira M., et al., “An updated evolutionary classification of CRISPR—Cas systems”, Nature Reviews Microbiology, vol. 13, 2015, pp. 722-736, DOI: 10.1038/nrmicro3569, (15 pages). [cited by applicant]
Mathiowitz, E., et al., “Novel Microcapsules for Delivery Systems”, Reactive Polymers, vol. 6, 1987, pp. 275-283 (9 pages). [cited by applicant]
Mathiowitz, E., et al., “Polyanhydride Microspheres as Drug Carriers I. Hot-Melt Microencapsulation”, Journal of Controlled Release, vol. 5, 1987, pp. 13-22 (10 pages). [cited by applicant]
Mathiowitz, E., et al., “Polyanhydride Microspheres as Drug Carriers. II. Microencapsulation by Solvent Removal”, Journal of Applied Polymer Science, vol. 35, 1988, pp. 755-775 (20 pages). [cited by applicant]
Paunovska, Kalina, et al., “A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation”, Nano Lett., vol. 18, No. 3, Mar. 14, 2018, pp. 2148-2157, … [cited by applicant]
Paunovska, Kalina, et al., “Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery”, ACS Nano, vol. 12, No. 8, Aug. 28, 2018, pp. 8341-8349, DOI: 10.1021/acsnano.8b… [cited by applicant]
Platt, Randall J., et al., “CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling”, Cell, vol. 159, Oct. 9, 2014, pp. 440-455, DOI: 10.1016/j.cell.2014.09.014 (16 pages). [cited by applicant]
Pollastri, M. P., et al., “Synthesis, structure, and thermal properties of 1,2-dipalmitoylgalloylglycerol (DPGG), a novel self-adhering lipid”, Chemistry and Physics of Lipids, vol. 104, 2000, pp. 67-74 (8 pages). [cited by applicant]
Ramishetti, Srinivas, et al., “Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles”, ACS Nano, vol. 9, No. 7, Jun. 4, 2015, pp. 6706-6716, DOI: 10.1021/acsnano.5b02796 (11 pages). [cited by applicant]
Sago, Cory D., et al., “High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing”, PNAS, vol. 115, No. 43, 2018, pp. E9944-E9952, Doi: 10.1073/pnas.1811276115… [cited by applicant]
Sago, Cory D., et al., “Modifying a commonly expressed endocytic receptor retargets nanoparticles in vivo”, Nano Lett., vol. 18, No. 12, Dec. 12, 2018, pp. 7590-7600, DOI: 10.1021/acs.nanolett.8b03149, Author Manuscript… [cited by applicant]
Sago, Cory D., et al., “Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution”, Journal of the American Chemical Society, vol. 140, No. 49, 2018, p. 17095-17105, DOI: 10.1021/jacs.8b0897… [cited by applicant]
Sharma, Padmanee, et al., “The future of immune checkpoint therapy”, Science, vol. 348, No. 6230, Apr. 3, 2015, pp. 56-61, DOI: 10.1126/science.aaa8172 (6 pages). [cited by applicant]
Shmakov, Sergey, et al., “Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems”, Molecular Cell, vol. 60, No. 3, 2015, pp. 385-397, DOI: 10.1016/j.molcel.2015.10.008, (14 pages). [cited by applicant]
Tavares, Anthony J., et al., “Effect and removing Kupffer cells on nanoparticle tumor delivery”, Proceedings of the National Academy of Sciences, vol. 114, No. 51, Dec. 5, 2017, pp. E10871-E10880, Doi: 10.1073/pnas. 171… [cited by applicant]
Tsoi, Kim M., et al., “Mechanism of hard nanomaterial clearance by the liver”, Nature Materials, vol. 15, No. 11, Nov. 2016, pp. 1212-1221, DOI: 10.1038/nmat4718, Author Manuscript (21 pages). [cited by applicant]
Ui-Tei, Kumiko, et al., “Sensitive assay of RNA interference in [cited by applicant]
Yokoe, Hiroko, et al., “Spatial dynamics of GFP-tagged proteins investigated by local fluorescence enhancement”, Nature Biotechnology, vol. 14, Oct. 1996, pp. 1252-1256 (5 pages). [cited by applicant]
Zetsche, Bernd, et al., “Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System”, Cell, vol. 163, No. 3, 2015, pp. 759-771, DOI: 10.1016/j.cell.2015.09.038, (15 pages). [cited by applicant]
International Search Report for PCT/US2023/027741 dated Oct. 13, 2023 (3 pages). [cited by applicant]
Chenthamara, et al., “Therapeutic efficacy of nanoparticles and routes of administration”, Biomaterials Research, vol. 23, No. 20, Nov. 21, 2019, DOI: 10.1186/s40824-019-0166-x (29 pages) (Exhibit A). [cited by applicant]
Epand, et al., “Role of the position of unsaturation on the phase behavior and intrinsic curvature of phosphatidylethanolamines”, Biophysical Journal, vol. 71, No. 4, pp. 1806-1810, Oct. 1996, DOI:10.1016/S0006-3495(96)… [cited by applicant]
Fenton, et al., “Synthesis and Biological Evaluation of lonizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes”, Advanced materials (Deerfield Beach, Fla.), vol. 29, No. 33, Sep. 2017, DOI:… [cited by applicant]
Reichmuth, et al., “mRNA vaccine delivery using lipid nanoparticles”, Therapeutic Delivery, vol. 7, No. 5, pp. 319-334, 2016, DOI: 10.4155/tde-2016-0006 (16 pages) (Exhibit C). [cited by applicant]
Scheidt, et al., “The interaction of small molecules with phospholipid membranes studied by 1H NOESY NMR under magic-angle spinning”, Acta Pharmacologica Sinica, vol. 29, No. 1, 2008, pp. 35-49, DOI:10.1111/j.1745-7254.… [cited by applicant]
Wang, et al., “Effects of various numbers and positions of cis double bonds in the sn-2 acyl chain of phosphatidylethanolamine on the chain-melting temperature”, The Journal of Biological Chemistry, vol. 274, No. 18, pp… [cited by applicant]
CAS SciFinder Search, Ionizable Lipid, 2025 (21 pages). [cited by applicant]
Google Search, Is Adamantyl Cycloalkyl, 2025 (4 pages). [cited by applicant]
Google Search, Why is adamantyl group on an ionizable lipid, 2025 (4 pages). [cited by applicant]
Partial Search Report for PCT/US2022/012867 dated Mar. 28, 2022 (3 pages). [cited by applicant]
Partial Search Report for PCT/US2022/012941 dated Mar. 21, 2022 (2 pages). [cited by applicant]
Partial Search Report for PCT/US2022/012951 dated Mar. 23, 2022 (2 pages). [cited by applicant]
Partial Search Report for PCT/US2022/012954 dated Mar. 23, 2022 (3 pages). [cited by applicant]
Kanasty, Rosemary, et al., “Delivery Materials for siRNA Therapeutics”, Nature Materials, vol. 12, No. 11, pp. 967-977, Nov. 2013, DOI: 10.1038/nmat3765 (11 pages). [cited by applicant]
Zhang, Xinfu, et al., “Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing”, Science Advances, vol. 6, No. 34, 2020, eabc2315, DOI: 10.1126/sciadv.abc2315, (9 pages). [cited by applicant]